Vascular Biogenics Ltd (VBLT)

[gr8db8]

VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting
TEL AVIV, Israel, May 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that data from two Phase 2 clinical studies of VB-111 will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 3 to June 7, 2016 in Chicago.

The ASCO presentation details are as follows:

Title: Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.
Abstract: #2074
Session Type: Poster Session
Session Title: Central Nervous System Tumors
Date: Saturday, June 4, 2016
Time: 1:00 PM – 4:30 PM
Location: Hall A
Poster Board: # 261
Presenter: Andrew Jacob Brenner, MD, PhD, The University of Texas Health Science Center at San Antonio

Title: Tumor responses and preliminary survival data in a phase 2 trial of ofranergene obadenovec (VB-111) combined with paclitaxel in patients with recurrent platinum resistant ovarian cancer.
Abstract: #5551
Session Type: Poster Session
Session Title: Gynecologic Cancer
Date: Monday, June 6, 2016
Time: 1:00 PM – 4:30 PM
Location: Hall A
Poster Board: # 374
Presenter: Richard T. Penson, MD, MRCP, Massachusetts General Hospital